Loading candles…
Strides Pharma Science Ltd operates in the pharmaceutical industry, specializing in the development and manufacturing of pharmaceutical products and niche finished dosage formulations. Its product range includes complex generics across multiple dosage forms such as tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. The company distributes its products in over 100 countries and maintains a manufacturing presence with seven facilities spanning four continents, of which four are approved by the US FDA. Strides Pharma Science Ltd has pursued an inorganic growth strategy to enter new markets, expand business and therapy segments, and enhance manufacturing infrastructure.
| Date |
|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 18 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 30 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 29 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 22 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.